155 related articles for article (PubMed ID: 23738911)
1. Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden.
Schramm SJ; Li SS; Jayaswal V; Fung DC; Campain AE; Pang CN; Scolyer RA; Yang YH; Mann GJ; Wilkins MR
Pigment Cell Melanoma Res; 2013 Sep; 26(5):708-22. PubMed ID: 23738911
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
Tembe V; Schramm SJ; Stark MS; Patrick E; Jayaswal V; Tang YH; Barbour A; Hayward NK; Thompson JF; Scolyer RA; Yang YH; Mann GJ
Pigment Cell Melanoma Res; 2015 May; 28(3):254-66. PubMed ID: 25490969
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs in malignant melanoma.
Völler D; Ott C; Bosserhoff A
Clin Biochem; 2013 Jul; 46(10-11):909-17. PubMed ID: 23360785
[TBL] [Abstract][Full Text] [Related]
4. Network-based co-expression analysis for exploring the potential diagnostic biomarkers of metastatic melanoma.
Wang LX; Li Y; Chen GZ
PLoS One; 2018; 13(1):e0190447. PubMed ID: 29377892
[TBL] [Abstract][Full Text] [Related]
5. The role of microRNAs in melanoma.
Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
[TBL] [Abstract][Full Text] [Related]
6. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA regulation of melanoma progression.
Bonazzi VF; Stark MS; Hayward NK
Melanoma Res; 2012 Apr; 22(2):101-13. PubMed ID: 22209751
[TBL] [Abstract][Full Text] [Related]
8. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
11. Coexpression network analysis identified that plakophilin 1 is associated with the metastasis in human melanoma.
Wang HZ; Wang F; Chen PF; Zhang M; Yu MX; Wang HL; Zhao Q; Liu J
Biomed Pharmacother; 2019 Mar; 111():1234-1242. PubMed ID: 30841437
[TBL] [Abstract][Full Text] [Related]
12. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
13. Melanoma inhibitory activity promotes melanoma development through activation of YBX1.
Schmid R; Meyer K; Spang R; Schittek B; Bosserhoff AK
Pigment Cell Melanoma Res; 2013 Sep; 26(5):685-96. PubMed ID: 23672612
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
15. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
16. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information.
Jayawardana K; Schramm SJ; Haydu L; Thompson JF; Scolyer RA; Mann GJ; Müller S; Yang JY
Int J Cancer; 2015 Feb; 136(4):863-74. PubMed ID: 24975271
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
Winnepenninckx V; van den Oord JJ
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
[TBL] [Abstract][Full Text] [Related]
18. AKT1 as the PageRank hub gene is associated with melanoma and its functional annotation is highly related to the estrogen signaling pathway that may regulate the growth of melanoma.
Zhao J; Zeng X; Song P; Wu X; Shi H
Oncol Rep; 2016 Oct; 36(4):2087-93. PubMed ID: 27573172
[TBL] [Abstract][Full Text] [Related]
19. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?
Schramm SJ; Menzies AM; Mann GJ
Melanoma Res; 2013 Dec; 23(6):423-5. PubMed ID: 24165033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
